Clinical Medicine Reviews in Therapeutics

Iloperidone is one of the newest second generation antipsychotic medications approved in the United States for the acute treatment of schizophrenia in adults. Iloperidone binds tightly to serotonin-2A (5HT2A) and dopamine-2 (D2) receptors with very little affinity to histamine-1 (H1) and muscarinic-1,2 (M1–2) receptors. The efficacy of iloperidone for the treatment of schizophrenia has been established in three 6 week trials, one 4 week trial, and three 52-week follow-up studies. Iloperidone is generally well tolerated. The most common adverse effects observed in clinical studies of iloperidone are dizziness, weight gain, sedation, tachycardia, and orthostatic hypotension. This medication may serve as an additional treatment option for patients with schizophrenia.